What is Pulmatrix Inc Annual Revenue?

Pulmatrix Inc Annual Revenue rose 6.96%, in the last year to $7.81 M. Its sector's average revenue growth for the last fiscal year was 7.48%.

What is Pulmatrix Inc Annual Net Profit?

Pulmatrix Inc Annual Net Profit rose 32.31% in the last year to $9.56 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

What is Pulmatrix Inc Price to Earning Ratio?

Pulmatrix Inc Price to Earning Ratio is -2.09, which is negative.

What is Pulmatrix Inc Stock Price?

Pulmatrix Inc Stock Price rose 172.14% and outperformed its sector by 175.89% in the past year.

What is Pulmatrix Inc Quarterly Net profit?

Pulmatrix Inc Quarterly Net profit rose 4.66% YoY to $1.99 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

What is Pulmatrix Inc Debt to Equity Ratio?

Pulmatrix Inc Debt to Equity Ratio is zero as the company is debt-free.

What is Pulmatrix Inc Return on Equity(ROE)?

Pulmatrix Inc Return on Equity(ROE) for the last financial year was -70.96%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Pulmatrix Inc Mutual Fund Holding?

Pulmatrix Inc Mutual Fund Holding increased by 0.13% in the last quarter to 3.08.

What is Pulmatrix Inc Institutional Holding?

Pulmatrix Inc Institutional Holding remained the same in the last quarter at 8.88%.

How is the Pulmatrix Inc today?

The Pulmatrix Inc today is trading in the down by -0.91% at 5.47.

How has Pulmatrix Inc performed historically?

The Pulmatrix Inc is currently trading down -0.91% on an intraday basis in the past week the index fell -17.87%. The index has been down -12.62% in the past quarter and rose 172.14% in the past year. You can view this in the overview section.

Pulmatrix Inc XNAS: PULM

Pulmatrix Inc Live Share Price Today, Share Analysis and Chart

Name: Pulmatrix Inc: Is Infosys Ltd. worth buying?
Item: Pulmatrix Inc
Rating: 1.82700
Author: Trendlyne DVM scores

Download real time

5.47 -0.05 (-0.91%)

47.40% Fall from 52W High

16,172 XNAS Volume

XNAS 08 Apr, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Pulmatrix Inc is on 15 Apr 2025 for the purpose of Pulmatrix Inc Annual General Meeting for 2024 See details

Pulmatrix Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	20
PE TTM Negative PE TTM Unavailable in chosen country	-2.1
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.1
Price to Book Below industry Median Unavailable in chosen country	2.2
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	8.9
Revenue Growth Qtr YoY % Negative Revenue Growth Qtr YoY % Unavailable in chosen country	-99.9
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	7
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	4.7
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	32.3
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-65,066.7
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-91.5
Piotroski Score Below industry Median Unavailable in chosen country	3
Rel Perf vs Sector quarter% Unavailable in chosen country	-5.8
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-71
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-43.5

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

17.0 / 100

Technically Neutral

56.1 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Pulmatrix Inc Stock Price Analysis

Day Price Range -0.9% 1 Day return Unavailable in chosen country	5.5 (LTP) 5.36.1 LowHigh
Week Price Range -17.9% 1 Week return Unavailable in chosen country	5.5 (LTP) 5.16.7 LowHigh
Month Price Range -23.6% 1 Month return Unavailable in chosen country	5.5 (LTP) 5.18.7 LowHigh
52 Week Price Range 172.1% 1 Year return Unavailable in chosen country	5.5 (LTP) 1.710.4 LowHigh

View full Share Price History

Pulmatrix Inc Live Price Chart

Switch to TradingView

Fetching data ...

Pulmatrix Inc Stock Analysis

Pulmatrix Inc stock analysis with key metrics, changes, and trends.

Pulmatrix Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$7.81 M	6.96%	positive	Annual Revenue rose 6.96%, in the last year to $7.81 M. Its sector's average revenue growth for the last fiscal year was 7.48%.
Annual Net Profit	$9.56 M	32.31%	positive	Annual Net Profit rose 32.31% in the last year to $9.56 M. Its sector's average net profit growth for the last fiscal year was -32.62%.
Price to Earning Ratio	-2.09	-	negative	Price to Earning Ratio is -2.09, which is negative.
Stock Price	$5.47	172.14%	positive	Stock Price rose 172.14% and outperformed its sector by 175.89% in the past year.
Quarterly Net profit	$1.99 M	4.66%	positive	Quarterly Net profit rose 4.66% YoY to $1.99 M. Its sector's average net profit growth YoY for the quarter was -47.55%.
Debt to Equity Ratio	-	-	positive	Debt to Equity Ratio is zero as the company is debt-free.
Return on Equity(ROE)	-70.96 %	-70.96%	negative	Return on Equity(ROE) for the last financial year was -70.96%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	3.08 %	0.13%	positive	Mutual Fund Holding increased by 0.13% in the last quarter to 3.08.
Institutional Holding	8.88 %	0%	neutral	Institutional Holding remained the same in the last quarter at 8.88%.

VIEW LESS

Loading data..

Pulmatrix Inc - Company Profile

What does Pulmatrix Inc do?

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Pulmatrix Inc Management structure

All Gross Remunerations are in USD

Mr. Teofilo David Raad

Chief Executive Officer, President and Director

2024

Gross Remuneration

Year

Ms. Margaret Wasilewski

Chief Medical Officer

2024

Gross Remuneration

Year

Mr. Peter Ludlum

Interim Chief Executive Officer, Interim Chief Financial Officer and Principal Accounting Officer

2024

Gross Remuneration

2024

Gross Remuneration

Year

Pulmatrix Inc Live Share Price Today, Share Analysis and Chart

47.40% Fall from 52W High

Pulmatrix Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Rel Perf vs Sector quarter%

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

ROE Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

RoA Annual %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Pulmatrix Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Pulmatrix Inc Live Price Chart

Pulmatrix Inc Stock Analysis

Pulmatrix Inc stock analysis with key metrics, changes, and trends.

Annual Revenue rose 6.96%, in the last year to $7.81 M. Its sector's average revenue growth for the last fiscal year was 7.48%.

Annual Net Profit rose 32.31% in the last year to $9.56 M. Its sector's average net profit growth for the last fiscal year was -32.62%.

Price to Earning Ratio is -2.09, which is negative.

Stock Price rose 172.14% and outperformed its sector by 175.89% in the past year.

Quarterly Net profit rose 4.66% YoY to $1.99 M. Its sector's average net profit growth YoY for the quarter was -47.55%.

Debt to Equity Ratio is zero as the company is debt-free.

Return on Equity(ROE) for the last financial year was -70.96%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.13% in the last quarter to 3.08.

Institutional Holding remained the same in the last quarter at 8.88%.

Pulmatrix Inc - Company Profile

What does Pulmatrix Inc do?

Pulmatrix Inc Management structure

Mr. Teofilo David Raad

Chief Executive Officer, President and Director

Ms. Margaret Wasilewski

Chief Medical Officer

Mr. Peter Ludlum

Interim Chief Executive Officer, Interim Chief Financial Officer and Principal Accounting Officer

Pulmatrix Inc Board of directors

Mr. Teofilo David Raad

Chief Executive Officer, President and Director

Mr. Michael J. Higgins

Chairman of the Board

Mr. Todd Bazemore

Independent Director

Dr. Richard P. Batycky, PhD

Independent Director

Mr. Anand Varadan

Independent Director

Dr. Christopher Cabell, F.A.C.C.,M.D.,M.H.S.

Independent Director

Pulmatrix Inc FAQ

How is Pulmatrix Inc today?

Pulmatrix Inc today is trading in the red, and is down by -0.91% at 5.47.

How has Pulmatrix Inc performed historically?

Pulmatrix Inc is currently trading down -0.91% on an intraday basis. In the past week the stock fell -17.87%. stock has been down -12.62% in the past quarter and rose 172.14% in the past year. You can view this in the overview section.